Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with
intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will
receive nivolumab.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Clatterbridge Cancer Centre NHS Foundation Trust